HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Moberg Pharma AB

www.mobergpharma.se

Latest From Moberg Pharma AB

Moberg Sells Consumer Health Portfolio To Pay For Rx Research Focus

Moberg had been expanding its OTC portfolio while also continuing trials for Rx ingredients including its MOB-015 formulation of terbinafine indicated for fingernail and toenail fungus. But $155m agreement with two investment groups will complete Moberg's divestment of consumer health brands.
OTC Drugs Consumer

Moberg Sells Consumer Health Portfolio To Pay For Focusing On Rx Research

Moberg had been expanding its OTC topical and nutritional supplement portfolio while also continuing trials for Rx ingredients including its MOB-015 formulation of terbinafine indicated for fingernail and toenail fungus. But $155m agreement with two investment groups will complete Moberg's divestment of consumer health brands and make it dedicated to R&D, regulatory matters and business development.

Commercial Business Strategies

Asia Deal Watch: MEI Partners ME-401 With Japan’s Kyowa Hakko Kirin, Following Chinese Deal With BeiGene

About a month after signing a development and commercialization partnership in China for its PI3K delta inhibitor, MEI signs a deal for Japanese rights to the compound with Kyowa Hakko Kirin. Cue and LG Chem partner to develop targeted T-cell therapies for cancer.

Deals Asia Pacific

Firms Spread Diaper Rash, Skin Care Brands, Move Lice Kit License In OTC Sector Deals

Randob Labs agreed to purchase the Balmex brand of baby and adult skin protectants from Moberg Pharma for $4.25m. Mission Pharmacal divested to MainPointe topical analgesic brand Thera-Gesic and the Dr. Smith’s line of infant and adult skin protectant ointments and sprays.

US States United States
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
      • Topical Delivery
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Moberg Derma AB
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Scandinavia
          • Sweden
  • Parent & Subsidiaries
  • Moberg Pharma AB
  • Senior Management
  • Anna Ljung, CEO
    Sarah Hellerfeldt, CFO
    Torbjörn Wärnheim, SVP, R&D
  • Contact Info
  • Moberg Pharma AB
    Phone: (46) 8 522 30 700
    Gustavslundsvägen 42
    Bromma
    Stockholm, SE-167 51
    Sweden
Advertisement
Advertisement
UsernamePublicRestriction

Register